Mitchell et al. report that the GLP-1 receptor agonist exenatide significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension, both acutely and after 12 weeks of dosing, in a randomized placebo-controlled trial. Here, GLP1R is linked to pseudotumor cerebri.